MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. (MIRM) reported positive results from its Phase 3 EXPAND study of LIVMARLI® for cholestatic pruritus in patients with ultra-rare liver diseases. The study met its primary and secondary endpoints, showing significant improvement in pruritus among pediatric patients. Mirum plans to file a supplemental New Drug Application in the U.S. in 2027.

Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.